This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Children with the cystic fibrosis (CF) are at risk for end stage lung disease associated with chronic inflammation and infection of the lower respiratory tract. Despite encouraging trends in long term survival over the past 20 years, pulmonary disease remains the most common cause of morbidity and mortality in patients with CF. Although anti-inflammatory therapy is generally thought to be of benefit to patients, there is no single agent currently in wide-spread use in this patient population, primarily due to concerns regarding the long-term safety of previously studied agents such as oral steroids and ibuprofen. The results of a recently completed study on the use of azithromycin in patients with CF were promising enough to prompt the Cystic Fibrosis Foundation to issue a news release to CF caregivers recommending consideration of its use in selected patients. This clinical research project is designed to characterize the anti-inflammatory effect of azithromycin in children placed on this treatment in our clinic at the University of Florida. The hypothesis to be tested is that a decline in sputum inflammatory markers accompanies clinical benefit in patients treated with azithromycin. Results will define the utility of this treatment as it relates to the purported mechanism of action. Findings will not only provide clinical information relevant to direct patient care, but will also complement our ongoing research efforts regarding the pathogenesis of lung disease in children with CF-related lung disease.
Showing the most recent 10 out of 266 publications
